Stock CELU CELULARITY INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Celularity Inc.

Equities

CELU

US1511902041

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
3.02 USD -1.63% Intraday chart for Celularity Inc. -0.33% +22.07%
Mar. 26 Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L CI
Mar. 20 Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy MT

Valuation

Fiscal Period: December 2019 2020 2021 2022
Capitalization 1 - - 632.1 187.1
Enterprise Value (EV) 1 - - 626 238.7
P/E ratio -1.12 x -1.27 x -3.43 x 14.3 x
Yield - - - -
Capitalization / Revenue - - 29.6 x 10.4 x
EV / Revenue - - 29.3 x 13.3 x
EV / EBITDA - - -4.86 x -1.72 x
EV / FCF - - -12,541,464 x -3,460,473 x
FCF Yield - - -0% -0%
Price to Book -7.28 x -4.97 x 6.4 x 0.97 x
Nbr of stocks (in thousands) - - 12,346 14,501
Reference price 2 99.50 110.0 51.20 12.90
Announcement Date 1/25/21 3/29/21 3/31/22 3/31/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022
Net sales 1 17.55 21.15 14.28 21.34 17.98
EBITDA 1 -66.25 -70.98 -69.92 -128.9 -138.8
EBIT 1 -71.04 -77.16 -78.09 -137.7 -148.3
Operating Margin -404.68% -364.88% -546.93% -645.35% -824.85%
Earnings before Tax (EBT) 1 -34.68 -268 -212.9 -100.1 14.2
Net income 1 -13.38 -211.9 -208.2 -100.1 14.19
Net margin -76.19% -1,001.94% -1,458.42% -469.27% 78.95%
EPS 2 -5.635 -88.75 -86.90 -14.93 0.9000
Free Cash Flow - -65.28 -71.7 -49.92 -68.98
FCF margin - -308.68% -502.2% -233.97% -383.73%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 1/25/21 1/25/21 3/29/21 3/31/22 3/31/23
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales 1 10.62 4.857 5.935 3.776 4.135 4.129 - 2.938
EBITDA - - - - - - - -
EBIT 1 10.9 -14.95 -41.61 4.175 -5.646 21.1 - -42.48
Operating Margin 102.6% -307.8% -701.16% 110.57% -136.54% 510.9% - -1,445.75%
Earnings before Tax (EBT) 1 49.94 -4.02 -62.87 47.84 4.782 24.45 - -47.95
Net income 1 49.94 -4.039 -62.87 47.83 4.799 24.43 - -47.95
Net margin 470.14% -83.16% -1,059.26% 1,266.58% 116.06% 591.77% - -1,632.03%
EPS 2 4.000 -0.3000 -4.800 3.200 0.3000 1.600 -4.100 -2.700
Dividend per Share - - - - - - - -
Announcement Date 11/12/21 3/31/22 5/16/22 8/9/22 11/10/22 3/31/23 5/22/23 8/14/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022
Net Debt 1 - - - - 51.6
Net Cash position 1 22 0.07 23.7 6.1 -
Leverage (Debt/EBITDA) - - - - -0.3718 x
Free Cash Flow - -65.3 -71.7 -49.9 -69
ROE (net income / shareholders' equity) - -118% -266% -170% 9.51%
ROA (Net income/ Total Assets) - -8.89% -10.2% -20.4% -22.7%
Assets 1 - 2,383 2,032 491.6 -62.42
Book Value Per Share 2 -50.30 -13.70 -22.20 8.000 13.40
Cash Flow per Share 2 9.290 1.170 2.260 3.000 0.9400
Capex 1 1.92 31.6 27.8 6.2 5.24
Capex / Sales 10.93% 149.31% 194.94% 29.07% 29.13%
Announcement Date 1/25/21 1/25/21 3/29/21 3/31/22 3/31/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CELULARITY INC. Stock Celularity Inc.
+22.07% 65.78M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CELU Stock
  4. Financials Celularity Inc.